In patients with SLCO1B1 variants, which inhibit hepatic uptake of drugs and bile acids, the elevated bile salts are predicted to trigger antimicrobial-induced cholestasis and liver inflammation (Li et al., 2012). The gene discussed is SLCO1B1; the disease is cholestasis.